Abbott TriClip tricuspid edge-to-edge repair (T-TEER) device shown on transesophageal echo (TEE). The device clips together the leaflets of the valve to form a better seal and reduce regurgitation without the need for open heart surgery. Photo by Dave Fornell

Cardiology societies push Medicare to pay for tricuspid TEER

Six multispecialty cardiovascular societies have called on CMS to approve Medicare payments for tricuspid transcatheter edge-to-edge repair (T-TEER).

Predicting sudden cardiac death after a heart attack may be impossible—for now

Researchers tried to crack the code, but they fell short time and time again. AI may offer potential as one way to finally find an answer, they added. 

money maze benjamin franklin reimbursement medicare

Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

Video of FDA Commissioner Robert Califf, MD, explaining the need for clinicians to take up fight against health misinformation with grassroots efforts in their communities. #misinformation #FDA #science

FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Sanjit Jolly, MD, says cholchicine failed to help heart attack patients in the CLEAR SYNERGY (OASIS 9) presented as a TCT 2024 late-breaker.

Cardiologist explores why colchicine failed to help heart attack patients

Sanjit S. Jolly, MD, MSc, reviewed his team's late-breaking data on treating heart attack patients with colchicine. "I think inflammation is an important area, but I don't think colchicine is the magic bullet," he said.

The Abbott Esprit BTK everolimus-eluting biosorbable scaffold system for below the knee peripheral artery disease on display at TCT 2024. Photo by Dave FornellTCTn 2024 DF

Bioresorbable BTK stent superior to ballon angioplasty at 2 years

Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.

Shockwave Javelin Peripheral IVL Catheter

Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients

Multiple late-breaking presentations at VIVA 2024 in Las Vegas focused on the benefits of treating peripheral artery disease with the company's intravascular lithotripsy portfolio.

Philippe Genereux, MD, explains the details of the EARLY TAVR trial, which compared early interventions vs. waiting in patients with asymptomatic severe aortic stenosis.

Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes

Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, discussed how a proactive treatment strategy for patients with asymptomatic AS can lead to better outcomes and improvements in quality of life.